News from Zyme and the companies we work with.
Dotmatics announces licensing agreement for informatics software with Compugen
Compugen selects Dotmatics’ cloud-based LIMS and ELN solution to drive efficient drug discovery Agreement marks the first implementation of Dotmatics SaaS technology in Israel, further extending global access Bishop’s Stortford, [...]
ERS Genomics licenses CRISPR gene editing technology to Otsuka Pharmaceutical
License to Nobel prize winning CRISPR technology supports internal research and development DUBLIN, Ireland, 03 March 2021: ERS Genomics Limited, which was formed to provide broad access to foundational CRISPR/Cas9 [...]
CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research
Funding will advance 3D lung cell culture models to accelerate drug discovery Cambridge, UK, 02 March 2021: CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise [...]
WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers
PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it [...]
ERS Genomics expands team with appointment of Jon Kratochvil as VP Business Development
Jon Kratochvil joins as Vice President for Business Development & Licensing for North America DUBLIN, Ireland, 01 March 2021: ERS Genomics Limited (“ERS”), which was formed to provide broad access [...]
Bio-Rad Introduces Bio-Plex Pro Human IgG SARS-CoV-2 Serology Assays
The Qualitative Multiplex Immunoassay Panel Provides Precise, Specific, and Sensitive Detection of IgG Antibodies Against Four SARS-CoV-2 Antigens HERCULES, Calif.–February 25, 2021–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global [...]
ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement
G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents Dublin, Ireland and Seoul, Korea, 23 February 2021: ERS Genomics Limited, which was formed to provide broad [...]
Optibrium appoints Dr Rae Lawrence as Director of Software Development
New role will drive development of AI-based drug discovery software solutions and lead development team expansion CAMBRIDGE, UK, 23 February 2021: Optibrium™, a developer of software for drug discovery, today [...]
Cell Guidance Systems’ nanoparticle cytokines enable use of macrophages to treat disease
Cambridge, UK, 19 February 2021: Cell Guidance Systems Ltd, a specialist in the control, manipulation and monitoring of cells, both in vitro and in vivo, today announced its POlyhedrin Delivery [...]
Avacta announces phase 1 Clinical Trial Authorisation (CTA) for AVA6000 approved by MHRA
Approval for phase 1 dose-escalation and expansion study of pre|CISION FAP-activated doxorubicin pro-drug Cambridge and Wetherby, 18 February 2021: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and [...]
ERS Genomics and ZeClinics sign CRISPR/Cas9 license agreement
ZeClinics is applying CRISPR technology to create gene edited zebrafish disease models Dublin, Ireland & Barcelona, Spain, 16 February 2021: ERS Genomics Limited, which was formed to provide broad access [...]
Avacta announces results of initial evaluation of SARS-CoV-2 lateral flow antigen test with clinical samples
Cambridge, UK 16 February 2021: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has received the first data for its SARS-CoV-2 rapid antigen [...]
